Page 15 - Shimadzu Nexera X2

Reducing the Time Required for Preparing Mobile Phases

Mobile Phase Blending Function — Convenient for Frequent Mobile Phase Changes During Method Development and Robustness Evaluation

With its flexibility in solvent delivery methods, the Nexera X2
85% A
offers a mobile phase blending function capable of blending
10% B
solvents at any mixture ratio desired. Mobile phase blending can X
5% C
be used to automate preparing buffer solutions, diluting
0% D Solvent Delivery
solvents, adding acids, and so on. Method development or Unit 1
50%
robustness evaluation may require preparing many different A
20%
types of mobile phases in small quantities. In such cases, the B Y
5%
mobile phase blending function can be used to automatically C
25% Solvent Delivery
prepare only the amounts necessary for analysis. This helps D Unit 2
reduce not only the amount of work required for preparation Solvent Blending Binary Gradient
but also the solvent consumption, thus making the process more Mobile phases are automatically Gradient analysis is performed
prepared using the pumps. using the mobile phases
environmentally friendly. automatically prepared.
Example of Mobile Phase Evaluation

This is an example of simultaneous analysis of non-steroidal anti-inflammatory drugs (NSAIDs). The method was evaluated
by loading the system with a total of five solvents—three used to prepare the phosphate buffer solution for solvent
delivery unit X and two (acetonitrile and methanol) for solvent delivery unit Y.

Mobile phase for solvent delivery unit X: A) Water; B) 20 mmol/L aqueous phosphate solution;
C) 20 mmol/L aqueous disodium phosphate solution
Mobile phase for solvent delivery unit Y: A) Acetonitrile; B) Methanol

pH study (3 types) Organic solvent study (5 types) Buffer solution concentration study (4 types)
12 types of mobile phases were prepared and analyzed automatically by the system.

5 %RSD of n = 6 1. Piroxicam
1: 0.396 2. Ketoprofene
2
2: 0.438 3. Diflunisal
3 3: 0.402 4. Flurbiprofen
8
4: 0.473 5. Ampiroxicam
5: 0.405 6. Etodolac
1 6: 0.418
7. Diclofenac
7 7: 0.455 8. Indomethacin
4
6 8: 0.441
0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 min
Repeatability was analyzed under conditions that provided good peak separation (n = 6).

15